Paloma Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Paloma Partners’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-47,713	Closed	-$321K	–	2430
2019 Q2	$321K	Buy	+47,713	New	+$409K	0.01%	1261
2017 Q3	–	Sell	-15,158	Closed	-$337K	–	2608
2017 Q2	$337K	Sell	15,158 -16,056	-51%	-$126K	﹤0.01%	1751
2017 Q1	$184K	Buy	+31,214	New	+$225K	﹤0.01%	1873
2014 Q3	–	Sell	-22,344	Closed	-$409K	–	1422
2014 Q2	$409K	Buy	+22,344	New	+$291K	0.02%	676

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Paloma Partners's AVEO Position: Q3 2019 in Review

Paloma Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2019, closing a stake of 47,713 shares — an estimated $321K sold.

Paloma Partners first reported a position in AVEO in Q2 2014 and held it in 4 quarters. The position peaked at $409K in Q2 2014. 59 funds tracked by Wall St. Rank hold AVEO as of Q3 2019.

Paloma Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 47,713 AVEO Pharmaceuticals, Inc. shares in Q3 2019, an estimated $321K.
Paloma Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2014 and held it in 4 quarters.
Paloma Partners's AVEO Pharmaceuticals, Inc. position peaked at $409K in Q2 2014.
59 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.